Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2012-03-06 Board/Management Inform…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo AB fokuserar verksamheten och minskar kostnaderna
Board/Management Information Classification · 1% confidence The document is a press release dated March 6, 2012, announcing a strategic focus, cost reduction, and potential staff reduction (up to 35 positions). This type of announcement, detailing internal restructuring, strategic shifts, and associated cost impacts, is generally classified as a significant corporate event announcement. It is not a formal financial report (like 10-K or IR), an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). Since it announces changes in operational structure and strategy that impact the company's future, it most closely aligns with a general corporate announcement. Given the provided definitions, it doesn't fit perfectly into the specific categories like MANG (board change) or CAP (financing). It is a significant operational update. In the absence of a specific 'Operational Update' or 'Strategy Change' code, and considering it is a formal announcement of corporate action, it falls best under the general regulatory/corporate announcement category, RNS, as a fallback for significant, non-standard filings.
2012-03-06 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-December 2011, containing comprehensive financial statements, management commentary, and operational updates. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis. Therefore, it fits the definition of an Interim/Quarterly Report. FY 2011
2012-01-31 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January-December 2011' and contains comprehensive financial statements, including income statements, cash flow data, and key performance indicators for the full year and the fourth quarter. It provides detailed management commentary on business operations, product sales, and clinical development programs. As it contains substantive financial data and analysis for a period shorter than a full fiscal year (or in this case, a year-end interim report), it is classified as an Interim/Quarterly Report. FY 2011
2012-01-31 English
Orexos forskningssamarbete avslutas och OX-CLI-/ OX-ESI-projekten läggs ned
Legal Proceedings Report Classification · 1% confidence The document is a short press release (1940 characters) announcing the termination of a research collaboration between Orexo AB and Janssen Pharmaceuticals regarding specific drug development programs (OX-CLI/OX-ESI). It mentions that further details can be found in the 'delårsrapport januari-december 2011' (interim report January-December 2011) on the company website. Since this document is an announcement about company events (collaboration termination) and directs the reader elsewhere for the detailed financial report, it is not the report itself. It is a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-specific corporate announcement that doesn't fit the other categories like Director's Dealing, Dividend Notice, or Capital Change. It is not a specific regulatory filing like a 10-K or an ER, but rather a news release about operational/legal matters.
2012-01-31 Swedish
Orexo’s drug discovery collaboration terminated and OX-CLI/OX-ESI projects end
Regulatory Filings Classification · 1% confidence The document is a short press release dated January 31, 2012, announcing the termination of a research collaboration between Orexo AB and Janssen Pharmaceuticals regarding specific drug discovery programs (OX-CLI and OX-ESI). It provides key operational news but does not contain detailed financial statements (ruling out 10-K or IR) or a full Q&A transcript (ruling out CT). It is an announcement of a significant business event. Since it is a general business update/press release that doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), it falls best under the general regulatory announcement category, RNS, as it is explicitly stated to be information disclosed pursuant to financial instruments trading acts.
2012-01-31 English
Positiva studieresultat för OX27
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces positive study results for a drug candidate (OX27). It includes quotes from the CEO, details about the drug's potential market, and concludes with a standard disclaimer stating that the information is what Orexo AB must disclose according to financial instrument laws. This format strongly suggests a general regulatory announcement rather than a specific periodic financial report (like 10-K or IR) or a detailed investor presentation (IP). Since it is a mandatory disclosure of material, non-financial news that doesn't fit other specific categories (like DIRS, DIV, CAP), the most appropriate general category is Regulatory Filings (RNS). The document length (3115 chars) is short, but it is the primary announcement itself, not an announcement *about* another report, so RPA is less fitting than RNS for this type of corporate news release.
2011-12-20 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.